Extended-infusion of Piperacillin-Tazobactam Versus Intermittent Infusion
Status:
Completed
Trial end date:
2020-01-26
Target enrollment:
Participant gender:
Summary
Continuous-infusion of piperacillin/tazobactam over 4 hrs instead of 30-minute intermittent
dosage regimen has shown observable outcomes. Our objective is to assess whether continuous
infusion of piperacillin/tazobactam is superior in terms of efficacy, safety and cost to the
intermittent regimen to treat suspected or proved infections due to gram negative bacteria.
The setting is Critical Care Medicine Department at Cairo University Hospitals. Methods A
prospective randomized comparative study.
Phase:
Phase 4
Details
Lead Sponsor:
Ain Shams University
Treatments:
Piperacillin Piperacillin, Tazobactam Drug Combination Tazobactam